Refile: BUZZ-Bausch + Lomb stops glaucoma eye drop development, US-listed shares drop
09/07/2026 22:15
REFILE-BUZZ-Bausch + Lomb stops glaucoma eye drop development, US-listed shares drop Corrects typographical error in headline
** New York-listed shares of contact lens maker Bausch + Lomb BLCO.K drop 2.9% to $16.25 in extended trading
** BLCO said it will end development of eye drops for glaucoma-related vision improvement after its mid-stage trial results did not meet its main goal
** Co, however, will continue to pursue a sustained-release implant for vision threatening diseases with a primary focus on geographic atrophy
** Brokerages rate the stock "hold" on average; their median PT is $18
** Stock is down 2% so far this year
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser